|
 |
Program
New Targets and Delivery Systems in Cancer Diagnosis and
Treatment Monday, March 5, 2007
| 8:00 am |
|
Welcome |
| |
|
|
Albert Deisseroth, MD, PhD |
| |
|
|
Nagy Habib, ChM, FRCS |
| |
|
|
Jan Schnitzer, MD
|
|
|
|
Ralph Weichselbaum, MD |
|
|
|
|
|
| 8:15 |
PLENARY KEY NOTE ADDRESS: |
|
|
|
|
The IKK Complex: Connecting Inflammation to Cancer
Michael Karin, PhD, University of California, San Diego, CA |
|
|
|
|
|
| |
SESSION I: TUMOR INFLAMMATION,
PROGENITOR CELLS AND THE IMMUNE RESPONSE
SESSION CHAIR: INDER VERMA |
| 9:00 |
|
Hematopoietic Precursers of Vasculogensis
Shanhin Raffii, MD, Weill Medical College of Cornell University & Georgia
Tech, New York, NY
|
| 9:30 |
|
NOVEL Cancer Models Using Lentiviral
Vectors
Inder Verma, PhD, The Salk Insitute, La Jolla, CA
|
| 10:00 |
|
Coffee Break |
| 10:30 |
|
Adoptive Cellular Immunotherapy for Solid
Cancers: Limitations and Future Opportunities
Marianne Hokland, MD, Aarhus University, Denmark |
| 11:00 |
|
Suppressor T-cells
David Klatzmann, MD, PhD, Hôpital Pitié-Salpêtrière,
Paris France |
| 11:30 |
|
Auto Immune Disease
Martin Weigert, PhD, Gwen Knapp Center for Lupus and Immunology, University
of Chicago, Chicago, IL
|
| 12:00 pm |
|
Harnessing the Immune System to Treat Minimal
Residual Disease
Christopher Contag, PhD, Stanford University School of Medicine, Stanford,
CA |
| 12:30 |
|
Lunch |
|
|
|
|
 |
|
| |
|
SESSION II: IMAGING TUMORS AND
THEIR MICROENVIRONMENT AND TARGETS
SESSION CHAIR: HARVEY HERSHMAN |
| 1:30 |
|
New Targets in the Tumor Stroma for Cancer
Therapy
Ralph Reisfeld, PhD, The Scripps Research Institute, La Jolla, CA |
| 2:00 |
|
Proteomic Mapping and Imaging of Endothelium
for Penetration into Solid Tumor
Jan E. Schnitzer, M.D., Sidney Kimmel Cancer Center, San Diego,
CA |
| 2:30 |
|
Imaging of Signal Transduction Pathways and Stem Cells
Juri Gelovani, MD, PhD, MD Anderson Cancer
Center, University of Texas, Houston, TX |
| 3:00 |
|
Coffee Break |
| 3:30 |
|
Biomedical Nanotechnology for In-vivo
Tumor Targeting and Imaging
Shuming Nie, PhD, Emory University and Georgia Tech, Atlanta, GA |
| |
|
| 4:00 |
|
Proteolytic Pathways as Therapeutic Targets in Cancer
Bonnie Sloane, PhD, Wayne State University of Medicine, Detroit,
MI |
| 4:30 |
|
Molecular Imaging of Cancer Progression &
Cancer Gene Therapy
Harvey Hershman, PhD, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles,
CA |
| 5:00 |
|
VISA to Cancer Therapy
Mien-Chie Hung, PhD, The University of Texas, MD Anderson Cancer
Center, Houston, TX |
| |
|
LATE BREAKING ORAL ABSTRACT PRESENTATIONS |
| 5:30 |
|
Selective Ablation of Metastatic Disease with
Integrin avB3 Targeted Nanoparticle Drug Delivery
Bharat Majeti, Moores UCSD Cancer Center, San Diego, CA |
| 5:45 |
|
A Novel Target for the Development of Ovarian Cancer
Diagnostics and Therapeutics
Kathleen Mulder, Penn State College of Medicine, Hershey, PA |
| 6:00 |
|
Apoptosis Improves the Distribution and Efficacy
of Replication-Competent Herpes Simplex Virus in Solid Tumor
Satoshi Nagano, Massachusetts General Hospital, Boston, MA |
| 6:15 |
|
Dissecting the Oncogenic Mechanism of
Cancer Specific Mutant P13K
Li Zhao, The Scripps Research Institute, San Diego, CA |
| 6:30 |
|
Adjourn to Welcome Reception |
| |
|
|
|
|
|
Tuesday, March
6, 2007
|
| |
KEY NOTE ADDRESS: |
| 8:00 am |
|
Drugging the Cancer Genome: Integrating
Molecular Targets and Biomarkers
Paul Workman, Cancer Research UK Centre for Cancer Therapeutics, The
Institute for Cancer Research, Sutton UK
|
|
SESSION III: NEW TARGETS IN CANCER
CELLS
SESSION CHAIR: DOUGLAS GREEN
|
| 8:45 |
|
Intracellular ROS
and Bcl-2 Family: Friends or Foes
Shazib Pervaiz , M.D, PhD, National University of Singapore
|
| 9:15 |
|
Passenger Proteins and the Regulation
of the Cell Cycle
Robert Margolis, PhD, Sidney Kimmel Cancer Center, San Diego, CA |
| 9:45 |
|
Mitochondria, p53, and Apoptosis
Douglas R. Green, PhD, St. Jude Children's Hospital, Memphis, TN
|
| 10:15 |
Coffee Break |
| 10:30 |
|
Phenotypes Override Genotypes in Normal
and Malignant Breast Tissue
Mina Bissell, PhD, Lawrence Berkeley National Laboratory, Berkeley,
CA
|
| 11:00 |
|
Ubiquitin-Dependent Proteolysis and Cell
Cycle Control
Charles Spruck, PhD, Sidney Kimmel Cancer Center, San Diego, CA |
| 11:30 |
|
DNA Damage and p21 Regulation
Arun Fotedar, MD, PhD, Sidney Kimmel Cancer Center, San Diego, CA |
12:00 pm
|
|
|
Role of Retroelement RNAs in Cancer
Alan Garen, PhD, Yale University, New Haven, CT
|
| 12:30 |
|
|
Lunch |
|
|
|
|
|
|
| |
|
SESSION IV: MOLECULAR AND CELLULAR
TARGETING, NANOMEDICINE AND VECTOR THERAPY
SESSION CHAIR: MINA BISSEL
|
| 1:30 |
|
|
|
Dancing with uPAR: Interaction
of Multiple Ligands with the Urokinase Plasminogen Activator Receptor
(uPAR)
Choreographs Tumor Progression
Andrew Mazar, Attenuon, LLC, San Diego, CA |
| 2:00 |
|
|
|
Systemic Delivery of Oncolytic
Viruses for Virotherapy
Leonard Seymour, BSc, PhD, Oxford University, Oxford, UK |
|
|
|
|
| 2:30 |
|
|
|
Angiogenesis Inhibition by Stabilizing the DFG/P-Loop
Interaction in Raf
David Cheresh, PhD, University of California, San Diego, CA |
| 3:00 |
|
|
|
Coffee Break |
| 3:30 |
|
|
|
Targeted Cancer Gene Therapy with a Novel
Activity of Tumor Tissue Penetration
Chae-OK Yun, PhD, Yonsei University of Medicine, Seoul, Korea
|
| 4:00 |
|
|
|
Vector Targeting of Cancer
David Curiel, MD, PhD, University of Alabama, Birmingham |
| 4:30 |
|
|
|
Molecular Therapy of Breast Cancer
Rakesh Kumar, PhD, UT MD Anderson Cancer Center, Houston, TX
|
|
|
|
|
| 5:00 |
|
|
|
Molecular Basis of Cell Fate Decision in Response
to Genotoxic Stress: Live or Die
Sam Lee, MD, PhD, Harvard Medical School, Boston, MA |
|
|
|
|
|
|
|
LATE BREAKING ORAL ABSTRACT
PRESENTATIONS
|
| 5:30 |
|
|
|
p14ARF/Topoisomerase I Complex Regulates Chemosensitivity
in a
Serine Phosphrylation Dependent Manner
Keya Bandyopadhyay, Sidney Kimmel Cancer Center, San Diego, CA |
| 5:45 |
|
|
|
Vector Vaccination Can Induce Potent
Immune Response
When Combined With Vector Targeted Chemotherapy
Hakan Akbulut, Ankara University School of Medicine, Ankara,
Turkey
|
|
|
|
|
| 6:00 |
|
|
|
EGFR/Src Kinase-Dependent Pathway of Tumor Cell
Invasion and Metastasis
Jill Ricono, Moores UCSD Cancer Center, San Diego, CA
|
| 6:15 |
|
|
|
Targeting Tumors Overexpressing EGFRs by Polymeric
Nanotherapeutics
Armed with Specific Monoclonal Antibodies and Doxorubicin
Tomas Mrkvan, Academy of Sciences, Prague, Czech Republic |
| 6:30 |
|
|
|
Adjourn to Wine and Cheese Reception and Poster Viewing
|
Wednesday, March
7, 2007
|
|
|
KEY NOTE ADDRESS:
|
|
|
|
|
|
| 8:00 am |
|
Targeting Immunoregulatory Cells as Novel Cancer Immunotherapy
Tyler Curiel, MD, San Antonio Cancer Institute, San Antonio,Texas |
| |
|
|
SESSION V: EMERGING STRATEGIES
FOR CANCER DIAGNOSIS AND TREATMENT
SESSION CHAIR: RALPH WEICHSELBAUM
|
| 8:45 |
|
|
|
Discovery of Novel Tumor Targets in Gynecologic
Cancer
Je Ho Lee, MD, Professor, Samsung Cancer Center, Sungkyunkwan University, Seoul,
Korea
|
| 9:15 |
|
|
|
Tumor Genotype Determines the Efficacy of Genetically
Modified HSV-1 in Experimental Tumors
Ralph Weichselbaum, MD, D.K. University of Chicago Hospital, Chicago,
IL
|
| 9:45 |
|
|
|
Vector Vaccines for Cancer
Albert Deisseroth, MD, PhD, Sidney Kimmel Cancer Center, San Diego, CA |
| 10:15 |
|
|
|
Virotherapy for Multiple Myeloma
Stephen Russell, MD, PhD, Mayo Clinic College of Medicine, Rochester, MN
|
| 10:45 |
|
|
|
Advances in Allogeneic Stem Cell Transplant
Richard Champlin, MD, MD Anderson Cancer Center, University of Texas, Houston,
TX |
| 11:15 |
|
|
|
Targeted and Shielded Adenovectors
Imre Kovesdi, PhD, VectorLogics, Birmingham, AL |
| 11:45 |
|
|
|
Vector Vaccine for AML
Farzin Farzaneh, PhD, The Rayne Institute, King's College London, UK |
| 12:15 pm |
Gene and Stem Cell Therapy
Nagy Habib, ChM, FRCS, Imperial College London, London, UK |
| 12:45 |
Vector Therapy of Glioblastoma
Noriyuki Kasahara, MD, PhD, University of California Los Angeles, Los Angeles,
CA |
| 1:15 |
Closing Remarks & Final Adjournment |
| |
|
|
|
|
| |
|
|
|
Program Subject to Change. Check back for updates
on this website. |
|
|
|
|
|
| | |
|
|
Back to Conference Home Page |
